Advertisement

Clinical and Translational Imaging

, Volume 6, Issue 6, pp 449–458 | Cite as

Role of myocardial 123I-mIBG innervation imaging in the diagnosis of neurodegenerative diseases

  • Albert Flotats
Expert Review
  • 22 Downloads
Part of the following topical collections:
  1. Cardiovascular

Abstract

Neurodegenerative diseases occur when neurons in the central and/or peripheral nervous systems lose function over time and ultimately die. They are characterized by common cellular and molecular mechanisms including protein aggregation and inclusion body formation, categorising each type of disease. Therefore, the definitive diagnosis is at post-mortem, based on pathology. However, the development of various molecular imaging techniques has enabled pathological changes to be inferred in vivo. Decreased myocardial 123I-mIBG uptake has been reported in some patients with neurodegenerative diseases. This review is aimed to synthesise the basis, methodology and clinical role of myocardial 123I-mIBG imaging in the diagnosis of certain neurodegenerative diseases, focusing on its utility to differentiate some neurodegenerative Parkinsonisms between them, and to differentiate dementia with Lewy bodies from Alzheimer’s disease and other dementias.

Keywords

123I-mIBG Myocardial innervation Neurodegenerative diseases Parkinsonisms Alzheimer's disease Differential diagnosis 

Notes

Compliance with ethical standards

Conflict of interest

The author has no conflict of interest.

Ethical approval

This article is a review article and does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Elbaz A, Carcaillon L, Kab S, Moisan F (2016) Epidemiology of Parkinson’s disease. Rev Neurol (Paris) 172:14–26CrossRefGoogle Scholar
  2. 2.
  3. 3.
    World Health Organization. http://www.who.int/news-room/facts-in-pictures/detail/dementia. Accessed 1 Jul 2018
  4. 4.
    Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/what-is-dementia. Accessed 1 Jul 2018
  5. 5.
    McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J et al (2004) Dementia with Lewy bodies. Lancet Neurol 3:19–28CrossRefPubMedGoogle Scholar
  6. 6.
    Ferman TJ, Boeve BF (2007) Dementia with Lewy bodies. Neurol Clin 25:741–747CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zaccai J, McCracken C, Brayne C (2005) A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34:561–566CrossRefPubMedGoogle Scholar
  8. 8.
    Shapiro B, Gross MD (1987) Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatric Oncol 15:170–177CrossRefGoogle Scholar
  9. 9.
    Jacobson AF, Travin MI (2015) Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature. J Nucl Cardiol 22:980–993CrossRefPubMedGoogle Scholar
  10. 10.
    Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, EANM Cardiovascular Committee, European Council of Nuclear Cardiology et al (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812CrossRefPubMedGoogle Scholar
  11. 11.
    Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67CrossRefPubMedGoogle Scholar
  12. 12.
    Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI et al (2001) Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac events. J Nucl Med 42:1757–1767PubMedGoogle Scholar
  14. 14.
    Somsen GA, Verberne HJ, Fleury E, Righetti A (2004) Normal values and within subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 11:126–133CrossRefPubMedGoogle Scholar
  15. 15.
    Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y et al (2014) Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 21:970–978CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Verschure DO, Poel E, Nakajima K, Okuda K, van Eck-Smit BLF, Somsen A et al (2018) A European myocardial 123I-mIBG cross-calibration phantom study. J Nucl Cardiol 25:1191–1197CrossRefPubMedGoogle Scholar
  17. 17.
    Nakajima K, Verschure DO, Okuda K, Verberne HJ (2017) Standardization of 123I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications. Clin Transl Imaging 5:255–263CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Goldstein DS (2013) Sympathetic neuroimaging. Handb Clin Neurol 117:365–370CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 38(suppl 2):2–7CrossRefPubMedGoogle Scholar
  20. 20.
    Cersosimo MG, Benarroch EE (2013) Central control of autonomic function and involvement in neurodegenerative disorders. Handb Clin Neurol 117:45–57CrossRefPubMedGoogle Scholar
  21. 21.
    Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J et al (2018) Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging 45:1534–1545CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRefPubMedGoogle Scholar
  23. 23.
    Kashihara K, Ohno M, Kawada S, Okumura Y (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med 47:1099–1101PubMedGoogle Scholar
  24. 24.
    Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ et al (2014) Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29:1010–1018CrossRefPubMedGoogle Scholar
  25. 25.
    Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Sato H, Takashima H et al (1999) Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 52:1269–1271CrossRefPubMedGoogle Scholar
  26. 26.
    Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y et al (1994) A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81–84CrossRefPubMedGoogle Scholar
  27. 27.
    Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH (1999) Cardiac uptake of [123I]mIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53:1020–1025CrossRefPubMedGoogle Scholar
  28. 28.
    Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H et al (2000) Cardiac Sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled mIBG. J Nucl Med 41:71–77PubMedGoogle Scholar
  29. 29.
    Raffel DM, Koeppe RA, Little R, Wang C, Liu S, Junck L et al (2006) PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J Nucl Med 47:1769–1777PubMedGoogle Scholar
  30. 30.
    Chiaravalloti A, Stefani A, Di Biagio D, Pierantozzi M, Tavolozza M, Di Pietro B et al (2013) Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease. Ann Nucl Med 27:444–451CrossRefPubMedGoogle Scholar
  31. 31.
    Takahashi M, Ikemura M, Oka T, Uchihara T, Wakabayashi K, Kakita A et al (2015) Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. J Neurol Neurosurg Psychiatry 86:939–944CrossRefPubMedGoogle Scholar
  32. 32.
    Langston JW, Wiley JC, Tagliati M (2018) Optimizing Parkinson’s disease diagnosis: the role of a dual nuclear imaging algorithm. NPJ Parkinson’s Dis 4:5CrossRefGoogle Scholar
  33. 33.
    Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 11:351–355CrossRefPubMedGoogle Scholar
  34. 34.
    Treglia G, Stefanelli A, Cason E, Cocciolillo F, Di Giuda D, Giordano A (2011) Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson’s disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 113:823–829CrossRefPubMedGoogle Scholar
  35. 35.
    Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G et al (2012) MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 22:43–55CrossRefPubMedGoogle Scholar
  36. 36.
    Orimo S, Suzuki M, Inaba A, Mizusawa H (2012) 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 18:494–500CrossRefPubMedGoogle Scholar
  37. 37.
    Hamada K, Hirayama M, Watanabe H, Kobayashi R, Ito H, Ieda T et al (2003) Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:423–426CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K et al (1999) Loss of 123I-MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 40:371–375PubMedGoogle Scholar
  39. 39.
    Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F (2006) Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 12:284–288CrossRefPubMedGoogle Scholar
  40. 40.
    Hattori T, Orimo S, Hallett M, Wu T, Inaba A, Azuma R et al (2014) Relationship and factor structure in multisystem neurodegeneration in Parkinson’s disease. Acta Neurol Scan 130:347–353CrossRefGoogle Scholar
  41. 41.
    Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, Saiki M et al (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220:105–111CrossRefPubMedGoogle Scholar
  42. 42.
    Chiaravalloti A, Stefani A, Tavolozza M, Pierantozzi M, Di Biagio D, Olivola E et al (2012) Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson’s disease: molecular imaging with 123I-MIBG. Mol Med Rep 6:1337–1342CrossRefPubMedGoogle Scholar
  43. 43.
    Dorschner J, Farmakis G, Behnke S, Hellwig D, Schneider S, Fassbender K et al (2011) Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 17:372–375CrossRefPubMedGoogle Scholar
  44. 44.
    Chung EJ, Kim EG, Kim MS, Bae SK, Seog DH, Oh SJ et al (2011) Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson’s dissease. J Clin Neurosci 18:922–925CrossRefPubMedGoogle Scholar
  45. 45.
    Mizutani Y, Nakamura T, Okada A, Suzuki J, Watanabe H, Hirayama M et al (2014) Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson’s disease. Parkinsonism Relat Disord 20:520–524CrossRefPubMedGoogle Scholar
  46. 46.
    Quattrone A, Bagnato A, Annesi G, Novellino F, Morgante L, Savettieri G et al (2008) Myocardial 123 metaiodobenzylguanidine uptake in genetic Parkinson’s disease. Mov Disord 23:21–27CrossRefPubMedGoogle Scholar
  47. 47.
    Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Courbon F, Brefel-Courbon C, Talamas C, Alibelli MJ, Berry I, Montastruc JL et al (2003) Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 18:890–897CrossRefPubMedGoogle Scholar
  49. 49.
    Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA et al (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85:404–412CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 89:88–100CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers et al (2017) Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging 52:228–242CrossRefPubMedGoogle Scholar
  53. 53.
    Treglia G, Cason E, Giordano A (2012) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between Dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 22:111–117CrossRefPubMedGoogle Scholar
  54. 54.
    Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M et al (2001) Cardiac 123I-meta-iodobenzylguanidine (mIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 70:781–783CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K et al (2006) Value of 123I-mIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850–1854CrossRefPubMedGoogle Scholar
  56. 56.
    Camacho V, Marquié M, Lleó A, Alvés L, Artigas C, Flotats A et al (2011) Cardiac sympathetic impairment parallels nigrostriatal degeneration in probable dementia with Lewy bodies. Q J Nucl Med Mol Imaging 55:476–483PubMedGoogle Scholar
  57. 57.
    Kobayashi S, Tateno M, Morii UK, Saito T (2009) Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies. Psychiatry Res 174:76–80CrossRefPubMedGoogle Scholar
  58. 58.
    Marquié Sayagués M, Da Silva AL, Molina-Porcel L, Alcolea Rodríguez D, Sala Matavera I, Sánchez-Saudinós MB et al (2010) (123)I-MIBG myocardial scintigraphy in the diagnosis of Lewy body dementia. Neurologia 25:414–421CrossRefPubMedGoogle Scholar
  59. 59.
    Flotats A, Carrió I (2004) Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 11:587–602CrossRefPubMedGoogle Scholar
  60. 60.
    Slaets S, Van Acker F, Versijpt J, Hauth L, Goeman J, Martin JJ et al (2015) Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int J Geriatr Psychiatry 30:864–869CrossRefPubMedGoogle Scholar
  61. 61.
    Estorch M, Camacho V, Paredes P, Rivera E, Rodríguez-Revuelto A, Flotats A et al (2008) Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 35:1636–1641CrossRefPubMedGoogle Scholar
  62. 62.
    Camacho V, Estorch M, Marquié M, Domènech A, Flotats A, Fernández A et al (2013) Utility of early imaging of myocardial innervation scintigraphy in the diagnosis of Lewy body dementia. Rev Esp Med Nucl Imagen Mol 32:77–80PubMedGoogle Scholar
  63. 63.
    Sakamoto F, Shiraishi S, Tsuda N, Ogasawara K, Yoshida M, Yuki H et al. (2016) 123I-MIBG myocardial scintigraphy for the evaluation of Lewy body disease: are delayed images essential? Is visual assessment useful? Br J Radiol 89:20160144CrossRefPubMedCentralGoogle Scholar
  64. 64.
    Yoshita M, Arai H, Arai T, Asada T, Fujishiro H, Hanyu H et al (2015) Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One 10:e0120540CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Orimo S, Yogo M, Nakamura T, Suzuki M, Watanabe H (2016) (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev 30:122–133CrossRefPubMedGoogle Scholar
  66. 66.
    Nakae I, Hayashi H, Mitsunami K, Horie M (2013) Clinical significance of lung iodine-123 metaiodobenzylguanidine uptake assessment in Parkinson’s and heart diseases. Ann Nucl Med 27:737–747CrossRefPubMedGoogle Scholar

Copyright information

© Italian Association of Nuclear Medicine and Molecular Imaging 2018

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentUniversitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant PauBarcelonaSpain

Personalised recommendations